Supplementary Figures S1-S7 from A novel type of monocytic leukemia stem cell revealed by the clinical use of venetoclax-based therapy

Supplementary Fig. 1: Immunophenotyping and WES analysis of primary AML specimens. Supplementary Fig. 2: Immunophenotyping of engrafted cells in PDX. Supplementary Fig. 3: WES analysis and remission duration of VEN/AZA relapsed AML patients. Supplementary Fig. 4: CITE-seq data analysis. Supplementary Fig. 5: Sorting strategies for determining m-LSC immunophenotype and expression of various LSC markers in m-LSCs. Supplementary Fig. 6: Molecular properties and targeting of m-LSCs in vitro and in vivo. Supplementary Fig. 7: M5 but not M4 patients showing significantly higher refractory rate to VEN/AZA therapy.